Pleno

Executive Summary

Pleno Inc. is a San Diego-based biotechnology company founded in 2019 that is reimagining genomics with its proprietary Hypercoding technology. The company is developing the RAPTOR instrument platform, which aims to provide faster, lower-cost, and higher-plex multiomic biomarker detection to enable AI-driven precision medicine at scale. By addressing the cost, complexity, and workflow limitations of current genomic testing platforms such as NGS, PCR, and microarrays, Pleno seeks to democratize multiomic analysis and accelerate the adoption of precision medicine. The company's innovative approach combines advanced molecular biology with machine learning, positioning it to capture significant value in the rapidly growing genomics market. While Pleno is still private and has not publicly disclosed its total funding or valuation, its technology has attracted attention from the biotech community, and the company is poised for potential milestones in the near term.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Announcement80% success
• Q4 2026First Commercial Launch of RAPTOR Platform60% success
• Q2 2026Strategic Partnership with Major Pharma or Diagnostics Company50% success